Çocukluk çağı kronik Hepatit B hastalığının klinik seyir ve tedavisi ile Serum CD 95 (FAS) ve Nitrik Oksid düzeyleri arasındaki ilişkinin belirlenmesi

Abstract

Amaç: Nitrik oksid (NO) ve CD 95’ in (FAS) kronik hepatit B enfeksiyonlarında inflamasyonda ve apoptozisde rol oynadığı düşünülmektedir. Bu çalışmada, kronik hepatit B enfeksiyonu olan çocukların serum NO ve CD 95 düzeylerinin sağlıklı çocuklarla karşılaştırmalı olarak incelenmesi amaçlandı. Yöntem: Kronik hepatit B tanısı ile izlenen 1-18 yaş arası 69 hasta çalışmaya dahil edildi. Kronik inaktif hepatit B enfeksiyonu olan 32 hasta (21 erkek, 11 kız) grup 1 olarak, kronik aktif hepatit B enfeksiyonu olan 37 hasta (25 erkek, 12 kız) grup 2 olarak ve 32 sağlıklı çocuk (18 erkek, 14 kız) kontrol grubu olarak sınıflandırıldı. Serum NO ve CD 95 düzeyleri ölçüldü. Hasta ve kontrol grubu karşılaştırmaları yapıldı. Bulgular: Ortalama yaş grup 1’ de 10.1±3.1 yıl, grup 2’ de 9.3±3.3 yıl ve kontrol grubunda 9.2±1.8 yıl bulundu (p>0.05). Hasta grubu ve kontrol grubu arasında serum NO ve CD 95 düzeyleri anlamlı farklılık gösterdi (sırasıyla 72.2±36.9’a karşılık 38.5±17.3 mµ, p<0.001 ve %36.5±11’ e karşılık %29.1±8.1, p<0.001). Grup 1’ in serum NO ve CD 95 düzeyleri kontrol grubundan daha yüksek bulundu (sırasıyla 73.7±38.9’a karşılık 38.5±17.3 mµ, p<0.01 ve %34.8±9.1’e karşılık %29.1±8.1, p<0.05). Grup 2’ nin serum NO ve CD 95 düzeyleri kontrol grubundan daha yüksek bulundu (sırasıyla 71.0±35.5’ e karşılık 38.5±17.3 mµ, p<0.01 ve %38.1±12.4’ e karşılık %29.1±8.1, p<0.05). Grup 1 ve Grup 2 arasında serum NO ve CD 95 düzeyleri anlamlı farklılık göstermedi (p>0.05). Sonuç: Serum NO ve CD 95 düzeylerinin kronik inaktif hepatit B enfeksiyonu olan çocuklarda ve kronik aktif hepatit B enfeksiyonu olan çocuklarda artış gösterdiği saptanmıştır.

Keywords

• Hepatit B virüs
• kronik hepatit B enfeksiyonu
• apoptozis
• CD 95 (FAS)
• nitrik oksid

Supporting Institution

Destekleyen bir kurum veya kuruluş yoktur.

The correlation between clinical prognosis together with the treatment of chronic Hepatitis B infection and Serum CD 95 (FAS) and Nitric Oxide levels in children

Abstract

Aim: Nitric oxide (NO) and CD 95 (FAS) are thought to play a role in inflammation and apoptosis in chronic hepatitis B infections. This study aimed to examine the serum NO and CD 95 levels of children with chronic hepatitis B infection in comparison with healthy children. Method: 69 patients between the ages of 1 and 18 who were diagnosed with chronic hepatitis B were included in the study. 32 patients (21 boys, 11 girls) with chronic inactive hepatitis B infection as group 1, 37 patients with chronic active hepatitis B infection (25 boys, 12 girls) as group 2 and 32 healthy children (18 boys, 14 girls) as control group were included. Serum NO and CD 95 levels were measured. Comparisons between patient and control groups were made. Results: The mean age was 10.1±3.1 years in group 1, 9.3±3.3 years in group 2 and 9.2±1.8 years in the control group (p>0.05). Serum NO and CD 95 levels showed significant differences between the patient group and the control group (72.2±36.9 vs. 38.5±17.3 mµ, p<0.001 and 36.5±11% vs. 29.1±8.1%, p<0.001, respectively). Serum NO and CD 95 levels of Group 1 were found to be higher than the control group (73.7±38.9 vs. 38.5±17.3 mµ, p<0.01 and 34.8±9.1% vs. 29.1±8.1%, p<0.05, respectively). Serum NO and CD 95 levels of Group 2 were found to be higher than the control group (71.0±35.5 vs. 38.5±17.3 mµ, p<0.01 and 38.1±12.4% vs. 29.1±8.1%, p<0.05, respectively). Serum NO and CD 95 levels did not show significant difference between Group 1 and Group 2 (p>0.05). Conclusion: Serum NO and CD 95 levels were found to increase in children with chronic inactive hepatitis B infection and in children with chronic active hepatitis B infection.

Keywords

• Hepatitis B virus
• chronic hepatitis B infection
• apoptosis
• CD 95 (FAS)
• nitric oxide (NO)

References

1. The World Health Organization. Hepatitis B. https://www.who.int/news-room/fact-sheets/detail/hepatitis-B. Temmuz 2023’de basıldı. Temmuz 2023’de erişildi.
2. Stinco M, Rubino C, Trapani S, Indolfi G. Treatment of hepatitis B virüs infection in children and adolescents. World J Gastroenterol. 2021;27(36):6053-6063. doi:10.3748/wjg.v27.i36.6053.
3. Indolfi G, Easterbrook P, Dusheiko G, et al. Hepatitis B virus infection in children and adolescents. Lancet Gastroenterol. Hepatol. 2019;4(6): 466–476. doi: 10.1016/S2468-1253(19)30042-1.
4. Türkiye Viral Hepatit Önleme ve Kontrol Programı 2018-2023. https://hsgm .saglik.gov.tr/depo/Yayinlarimiz/Programlar/Turkiye_Viral_Hepatit_Onleme_ve_Kontrol_Programi_2018-2023.pdf;2018.
5. McMahon BJ, Alward WL, Hall DB, et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis. 1985;151(4):599–603. doi: 10.1093/infdis/151.4.599.
6. Wyllie AH, Kerr JF, Currie AR. Cell death: the significance of apoptosis. Int Rev Cytol. 1980;68:251-306. doi: 10.1016/s0074-7696(08)62312-8.
7. Kiraz S, Ertenli I, Oztürk MA, et al. Increased soluble FAS suggest delayed apoptosis in Familial Mediterranean Fever complicated with amyloidozis. J Rheum. 2003;30(2):313-315.
8. Rudin CM, Thompson CB. Apoptosis and Disease: Regulation and Clinical relevance of Programmed Cell Death. Annu. Rev. Med. 1997;48:267-281. doi: 10.1146/annurev.med.48.1.267.

9. Hetts SW. To Die or Not To Die. Jama. 1998; 279(4): 300-307. doi: 10.1001/jama.279.4.300. PMID: 9450715.
10. Rust C, Gores GJ. Apoptosis and Liver disease. Am J Med. 2000;108(7):567-574. doi: 10.1016/s0002-9343(00)00370-3.
11. Andreoli TE. The Apopitotic Syndromes. Am J Med. 1999; 107(5): 488.doi: 10.1016/s0002-9343(99)00258-2.
12. Panossian A, Hambartsumyan M, Panosyan L, et al. Plasma nitric oxide level in Familial Mediterranean Fever and its modulations by Immuno-Guard. Nitric Oxide. 2003; 9(2): 103-110. doi: 10.1016/j.niox.2003.08.005.
13. Braderick A. Clinical manifestations and diagnosis of hepatitis B virüs infection in children and adolescant. UpToDate. Avaible from: http://www uptodate.com. Nisan 2023’de basıldı. Temmuz 2023’de erişildi.
14. Oksuz M, Akkiz H, Isiksal YF, et al. Expression of Fas antigen in liver tissue of patients with chronic hepatitis B and C. Eur J Gastroenterol Hepatol. 2004;16(3): 341-345. doi: 10.1097/00042737-200403000-00015.
15. Mochizuki K, Hayashi N, Hiramatsu N, et al. Fas Antigen Expression in Liver Tissues of Patients With Chronic Hepatitis B. J Hepatol. 1996;24(1):1-7. doi:10.1016/s0168-8278(96)80178-4.
16. Lapinski TW, Kowalczuk O, Prokopowicz D, Chyzewski L. Serum concentration of sFas and sFasL in healty HbsAg carriers, chronic viral hepatitis B and C patients. World J Gastroenterol. 2004;10(24):3650-3653. doi: 10.3748/wjg.v10.i24.3650.
17. Song le H, Binh VQ, Duy DN, et al. Variations in the serum concentrations of soluble Fas and soluble Fas ligand in Vietnamese patients infected with hepatitis B virus. J Med Virol. 2004;73(2):244-249. doi: 10.1002/jmv.20082.
18. Hamazaki K, Gochi A, Matsubara N, Mori M, Orita K. Expression of Fas antigen and Bcl-2 protein in hepatocelluler carsinoma. Acta Med. 1995;49(4):227-230. doi: 10.18926/AMO/30379.
19. Knowles RG, Moncada S. Nitric oxide synthases in mammals. Biochem J. 1994;298:249-258.
20. Guidotti LG, Guilhot S, Chisara FV. Interleukin-2 and alpha/beta interferon downregulate hepatitis B virus gene expression in vivo by tumor necrosis factor-dependent and independent pathways. J Virol.1994;68(3):1265-1270. doi:10.1128/JVI.68.3.1265-1270.1994.
21. Koulentaki M, Notas G, Petinaki E, et al. Nitric oxide and pro-inflammatory cytokines in acute hepatitis B. Eur J Intern Med.2004;15(1):35-38. doi: 10.1016/j.ejim.2003.11.004.
22. Wang K, Han LY, Lu Q, Wang B, Li XH, Wang HM. Nitric oxide and nitric oxide synthase in patients with chronic hepatitis B. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2005; 19(2): 142-145.
23. Liu RH, Jacop JR, Tennant BC, Hotchkiss JH. Nitrite and nitrosamine synthesis by hepatocytes isolated from normal woodchucks (Marmota monax) and woodchucks chronically infected with woodhuck hepatitis virus. Cancer Res. 1992;52(15):4139-4143.
24. Ersoy Y, Bayraktar M, Mızrak B, et al. The level of endothelin-1 and nitric oxide in patients with chronic viral hepatitis B and C and correlation with histopatological grading and staging. Hepatol Res. 2006; 34(2): 111-116. doi: 10.1016/j.hepres.2005.11.005
25. Amaro MJ, Bartolome J, Pardo M, Cotonat T, Lopez A, Carreno V. Decreased nitric oxide production in chronic viral hepatitis B and C. J Med Virol.1997;51(4):326-331. doi: 10.1002/(sici)1096-9071(199704)51:4<326::aid-jmv11>3.0.co;2-g.